85 related articles for article (PubMed ID: 17665889)
21. Pyrrolone Derivatives as Intracellular Allosteric Modulators for Chemokine Receptors: Selective and Dual-Targeting Inhibitors of CC Chemokine Receptors 1 and 2.
Ortiz ZacarÃas NV; van Veldhoven JPD; Portner L; van Spronsen E; Ullo S; Veenhuizen M; van der Velden WJC; Zweemer AJM; Kreekel RM; Oenema K; Lenselink EB; Heitman LH; IJzerman AP
J Med Chem; 2018 Oct; 61(20):9146-9161. PubMed ID: 30256641
[TBL] [Abstract][Full Text] [Related]
22. Human Naive T Cells Express Functional CXCL8 and Promote Tumorigenesis.
Crespo J; Wu K; Li W; Kryczek I; Maj T; Vatan L; Wei S; Opipari AW; Zou W
J Immunol; 2018 Jul; 201(2):814-820. PubMed ID: 29802127
[TBL] [Abstract][Full Text] [Related]
23. Directed evolution of broadly crossreactive chemokine-blocking antibodies efficacious in arthritis.
Angelini A; Miyabe Y; Newsted D; Kwan BH; Miyabe C; Kelly RL; Jamy MN; Luster AD; Wittrup KD
Nat Commun; 2018 Apr; 9(1):1461. PubMed ID: 29654232
[TBL] [Abstract][Full Text] [Related]
24. Crosstalk between stromal components and tumor cells of TNBC via secreted factors enhances tumor growth and metastasis.
Jin K; Pandey NB; Popel AS
Oncotarget; 2017 Sep; 8(36):60210-60222. PubMed ID: 28947965
[TBL] [Abstract][Full Text] [Related]
25. Transition-Metal-Free Decarboxylative Iodination: New Routes for Decarboxylative Oxidative Cross-Couplings.
Perry GJP; Quibell JM; Panigrahi A; Larrosa I
J Am Chem Soc; 2017 Aug; 139(33):11527-11536. PubMed ID: 28735532
[TBL] [Abstract][Full Text] [Related]
26. Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases.
Ha H; Debnath B; Neamati N
Theranostics; 2017; 7(6):1543-1588. PubMed ID: 28529637
[TBL] [Abstract][Full Text] [Related]
27. Multiple anti-tumor effects of Reparixin on thyroid cancer.
Liotti F; De Pizzol M; Allegretti M; Prevete N; Melillo RM
Oncotarget; 2017 May; 8(22):35946-35961. PubMed ID: 28415590
[TBL] [Abstract][Full Text] [Related]
28. Allosteric Modulation of Chemoattractant Receptors.
Allegretti M; Cesta MC; Locati M
Front Immunol; 2016; 7():170. PubMed ID: 27199992
[TBL] [Abstract][Full Text] [Related]
29. Multi-Functional Diarylurea Small Molecule Inhibitors of TRPV1 with Therapeutic Potential for Neuroinflammation.
Feng Z; Pearce LV; Zhang Y; Xing C; Herold BK; Ma S; Hu Z; Turcios NA; Yang P; Tong Q; McCall AK; Blumberg PM; Xie XQ
AAPS J; 2016 Jul; 18(4):898-913. PubMed ID: 27000851
[TBL] [Abstract][Full Text] [Related]
30. A Neutrophil Phenotype Model for Extracorporeal Treatment of Sepsis.
Malkin AD; Sheehan RP; Mathew S; Federspiel WJ; Redl H; Clermont G
PLoS Comput Biol; 2015 Oct; 11(10):e1004314. PubMed ID: 26468651
[TBL] [Abstract][Full Text] [Related]
31. G protein-coupled receptors in stem cell maintenance and somatic reprogramming to pluripotent or cancer stem cells.
Choi HY; Saha SK; Kim K; Kim S; Yang GM; Kim B; Kim JH; Cho SG
BMB Rep; 2015 Feb; 48(2):68-80. PubMed ID: 25413305
[TBL] [Abstract][Full Text] [Related]
32. A pilot study on reparixin, a CXCR1/2 antagonist, to assess safety and efficacy in attenuating ischaemia-reperfusion injury and inflammation after on-pump coronary artery bypass graft surgery.
Opfermann P; Derhaschnig U; Felli A; Wenisch J; Santer D; Zuckermann A; Dworschak M; Jilma B; Steinlechner B
Clin Exp Immunol; 2015 Apr; 180(1):131-42. PubMed ID: 25402332
[TBL] [Abstract][Full Text] [Related]
33. Targeting the minor pocket of C5aR for the rational design of an oral allosteric inhibitor for inflammatory and neuropathic pain relief.
Moriconi A; Cunha TM; Souza GR; Lopes AH; Cunha FQ; Carneiro VL; Pinto LG; Brandolini L; Aramini A; Bizzarri C; Bianchini G; Beccari AR; Fanton M; Bruno A; Costantino G; Bertini R; Galliera E; Locati M; Ferreira SH; Teixeira MM; Allegretti M
Proc Natl Acad Sci U S A; 2014 Nov; 111(47):16937-42. PubMed ID: 25385614
[TBL] [Abstract][Full Text] [Related]
34. Discovery of 2-[5-(4-Fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic Acid (SX-517): Noncompetitive Boronic Acid Antagonist of CXCR1 and CXCR2.
Maeda DY; Peck AM; Schuler AD; Quinn MT; Kirpotina LN; Wicomb WN; Fan GH; Zebala JA
J Med Chem; 2014 Oct; 57(20):8378-97. PubMed ID: 25254640
[TBL] [Abstract][Full Text] [Related]
35. Aryltriflates as a Neglected Moiety in Medicinal Chemistry: A Case Study from a Lead Optimization of CXCL8 Inhibitors.
Moriconi A; Bigogno C; Bianchini G; Caligiuri A; Resconi A; Dondio MG; D'Anniballe G; Allegretti M
ACS Med Chem Lett; 2011 Oct; 2(10):768-73. PubMed ID: 24900265
[TBL] [Abstract][Full Text] [Related]
36. Rationale and Means to Target Pro-Inflammatory Interleukin-8 (CXCL8) Signaling in Cancer.
Campbell LM; Maxwell PJ; Waugh DJ
Pharmaceuticals (Basel); 2013 Aug; 6(8):929-59. PubMed ID: 24276377
[TBL] [Abstract][Full Text] [Related]
37. Pd(0)-catalyzed 1,1-diarylation of ethylene and allylic carbonates.
Saini V; Liao L; Wang Q; Jana R; Sigman MS
Org Lett; 2013 Oct; 15(19):5008-11. PubMed ID: 24047468
[TBL] [Abstract][Full Text] [Related]
38. Suzuki coupling of potassium cyclopropyl- and alkoxymethyltrifluoroborates with benzyl chlorides.
Colombel V; Rombouts F; Oehlrich D; Molander GA
J Org Chem; 2012 Mar; 77(6):2966-70. PubMed ID: 22390789
[TBL] [Abstract][Full Text] [Related]
39. Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2 non-competitive allosteric inhibitor.
Bertini R; Barcelos LS; Beccari AR; Cavalieri B; Moriconi A; Bizzarri C; Di Benedetto P; Di Giacinto C; Gloaguen I; Galliera E; Corsi MM; Russo RC; Andrade SP; Cesta MC; Nano G; Aramini A; Cutrin JC; Locati M; Allegretti M; Teixeira MM
Br J Pharmacol; 2012 Jan; 165(2):436-54. PubMed ID: 21718305
[TBL] [Abstract][Full Text] [Related]
40. Pharmacological modulation of chemokine receptor function.
Scholten DJ; Canals M; Maussang D; Roumen L; Smit MJ; Wijtmans M; de Graaf C; Vischer HF; Leurs R
Br J Pharmacol; 2012 Mar; 165(6):1617-1643. PubMed ID: 21699506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
